Susquehanna Portfolio Strategies
AVBP icon

Susquehanna Portfolio Strategies’s ArriVent BioPharma AVBP Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Sell
9,670
-2,582
-21% -$76.2K 0.01% 732
2026
Q1 		$283K Buy
+12,252
New +$277K ﹤0.01% 851
2025
Q3 		– Sell
-20,056
Closed -$437K – 1121
2025
Q2 		$437K Buy
+20,056
New +$416K 0.01% 686

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Susquehanna Portfolio Strategies's AVBP Position: Q2 2026 in Review

Susquehanna Portfolio Strategies reduced its ArriVent BioPharma (AVBP) stake by 21% in Q2 2026, selling an estimated $76.2K and leaving 9,670 shares worth $336K. The position accounts for 0.01% of the portfolio, ranked #732.

Susquehanna Portfolio Strategies first reported a position in AVBP in Q2 2025 and has held it in 3 quarters since. The position peaked at $437K in Q2 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Susquehanna Portfolio Strategies held 9,670 shares of ArriVent BioPharma worth $336K as of Q2 2026.
  • Susquehanna Portfolio Strategies sold 2,582 ArriVent BioPharma shares in Q2 2026, an estimated $76.2K.
  • ArriVent BioPharma made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #732 holding.
  • Susquehanna Portfolio Strategies first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 3 quarters since.
  • Susquehanna Portfolio Strategies's ArriVent BioPharma position peaked at $437K in Q2 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.